Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study

BACKGROUND & AIMS: Short duration treatment may aid HCV elimination among key populations. This study evaluated the efficacy of glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection. METHODS: In this single-arm multicentre international trial, adults with recent HCV (durati...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinello, Marianne, Bhagani, Sanjay, Shaw, David, Orkin, Chloe, Cooke, Graham, Gane, Edward, Iser, David, Ustianowski, Andrew, Kulasegaram, Ranjababu, Stedman, Catherine, Tu, Elise, Grebely, Jason, Dore, Gregory J., Nelson, Mark, Matthews, Gail V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522905/
https://www.ncbi.nlm.nih.gov/pubmed/37771545
http://dx.doi.org/10.1016/j.jhepr.2023.100867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522905/
https://www.ncbi.nlm.nih.gov/pubmed/37771545
http://dx.doi.org/10.1016/j.jhepr.2023.100867

Ejemplares similares